Agilent Technologies, Inc.
A
株式のランク
#504
Agilent Technologies, Inc. delivers specialized, application-focused... Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
株価
$169.80
最終同期: 2026-10-19
時価総額
$47.88B
変化（1日）
-1.75%
変化（1年）
18.74%
国
US
取引 Agilent Technologies, Inc. (A)
カテゴリー
Healthcare
Agilent Technologies, Inc.（A）のP/E比率
October 2026 時点のP/E比率 TTM 34.18
Agilent Technologies, Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は 34.18 です。2024 年末時点での P/E は 29.32 でした。
Agilent Technologies, Inc. の P/E 比率の履歴（2000 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 34.18 | 7.53% |
| 2025 | 31.79 | 8.43% |
| 2024 | 29.32 | 19.62% |
| 2023 | 24.51 | -25.70% |
| 2022 | 32.99 | -16.40% |
| 2021 | 39.46 | -10.06% |
| 2020 | 43.87 | 97.56% |
| 2019 | 22.21 | -66.26% |
| 2018 | 65.82 | 105.51% |
| 2017 | 32.03 | 3.72% |
| 2016 | 30.88 | -1.53% |
| 2015 | 31.36 | 30.78% |
| 2014 | 23.98 | 40.24% |
| 2013 | 17.10 | 120.07% |
| 2012 | 7.77 | -14.53% |
| 2011 | 9.09 | -27.90% |
| 2010 | 12.61 | -106.38% |
| 2009 | -197.44 | -2,475.14% |
| 2008 | 8.31 | -48.91% |
| 2007 | 16.27 | 420.46% |
| 2006 | 3.13 | -95.86% |
| 2005 | 75.57 | 246.76% |
| 2004 | 21.79 | -664.77% |
| 2003 | -3.86 | -7.51% |
| 2002 | -4.17 | -110.20% |
| 2001 | 40.89 | 120.97% |
| 2000 | 18.51 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| 36.15 | 5.76% |
US
|
|
| 39.77 | 16.35% |
US
|
|
| -290.26 | -949.09% |
US
|
|
| - | - |
CN
|
|
| 37.15 | 8.67% |
US
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。